Phospho-Serine-118 Estrogen Receptor-α Detection in Human Breast Tumors in Vivo

Clinical Cancer Research

Volumn 10, Issue 4, 2004, Pages 1354-1359

  Murphy, Leigh ^a   Cherlet, Tracy ^a   Adeyinka, Adewale ^a,b   Niu, Yulian ^a   Snell, Linda ^a   Watson, Peter ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHOSERINE; PROGESTERONE RECEPTOR;

ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST TUMOR; CANCER GRADING; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIGAND BINDING; LYMPH NODE METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR BIOPSY; VALIDATION PROCESS; WESTERN BLOTTING;

BIOPSY; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL LINE, TUMOR; ENZYME INHIBITORS; ESTROGEN RECEPTOR ALPHA; FLAVONOIDS; HUMANS; IMMUNOHISTOCHEMISTRY; LIGANDS; LYMPHATIC METASTASIS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; PHENOTYPE; PHOSPHORYLATION; PHOSPHOSERINE; PROGNOSIS; RECEPTORS, ESTROGEN; SERINE; TUMOR MARKERS, BIOLOGICAL;

EID: 1642387680     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0112     Document Type: Article

References (28)

1. Osborne, C. Steroid hormone receptors in breast cancer management. Breast Cancer Res. Treat., 51: 227-238, 1998.
2. Fisher, B., Costantino, J., Redmond, C., Poisson, R., Bowman, D., Couture, J., Dimitrov, N., Wolmark, N., Wickerham, D., et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N. Engl. J. Med., 320: 479-484, 1989.
3. Fisher, B., Constantino, J., Wickerham, D., Redmond, C., Kovanah, M., Cronin, W., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wiend, S., Tan-Chiu, E., Ford, L., and Wolmark, N. Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl. Cancer Inst. (Bethesda), 90: 1371-1388, 1998.
4. Clarke, R., Leonessa, F., Welch, J., and Skaar, T. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol. Rev., 53: 25-71, 2001.
5. Robertson, J. Oestrogen receptor: a stable phenotype in breast cancer. Br. J. Cancer, 73: 5-12, 1996.
6. Kuukasjarvi, T., Kononen, J., Helin, H., Holli, K., and Isola, J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J. Clin. Oncol., 14: 2584-2589, 1996.
7. Lannigan., D. Estrogen receptor phosphorylation. Steroids, 68: 1-9, 2003.
8. Joel, P., Traish, A., and Lannigan, D. Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase. J. Biol. Chem., 273: 13317-13323, 1998.
9. Chen, D., Washbrook, E., Sarwar, N., Bates, G., Pace, P., Thirunuvakkarasu, V., Taylor, J., Epstein, R., Fuller-Pace, F., Egly, J., Coombes, R., and Ali, S. Phosphorylation of human estrogen receptor α at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene, 21: 4921-4931, 2002.
10. Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., Metzger, D., and Chambon, P. Activation of the estrogen receptor through phosphorylation by mitgen activated protein kinase. Science (Wash. DC), 270: 1491-1494, 1995.
11. Bunone, G., Briand, P-A., Miksicek, R., and Picard, D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phorphorylation. EMBO J., 15: 2174-2183, 1996.
12. Migliaccio, A., Domenico, M. d., Castoria, G., Falco, A. d., Bontempo, P., Nola, E., and Aurrichio, F. Tyrosine kinase/p21ras/MAP kinase pathway activation by estradiol receptor complex in MCF 7 cells. EMBO J., 15: 1292-1300, 1996.
13. Hiller, T., Snell, L., and Watson, P. Microdissection/RT-PCR analysis of gene expression. Biotechniques, 21: 38-44, 1996.
14. Coutts, A., and Murphy, L. Elevated mitogen activated protein kinase activity in estrogen non-responsive human breast cancer cells. Cancer Res., 58: 4071-4074, 1998.
15. Peng, B., Lu, B., Leygue, E., and Murphy, L. Putative functional characteristics of human estrogen receptor-β isoforms. J. Mol. Endocrinol., 30: 13-29, 2003.
16. Laemmli, U. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond), 227: 680-685, 1970.
17. Adeyinka, A., Niu, Y., Cherlet, T., Snell, L., Watson, P., and Murphy, L. Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin. Cancer Res., 8: 1747-1753, 2002.
18. Atanaskova, N., Keshamouni, V., Krueger, J., Schwartz, J., Miller, F., and Reddy, K. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. Oncogene, 21: 4000-4008, 2002.
19. Riera, J., Simpson, J., Tamayo, R., and Battifora, H. Use of cultured cells as a control for quantitative immunohistochemical analysis of estrogen receptor in breast cancer. Am. J. Clin. Pathol., 111: 329-335, 1999.
20. Leygue, E., Dotzlaw, H., Watson, P., and Murphy, L. Altered estrogen receptor α and β mRNA expression during human breast tumorigenesis. Cancer Res., 58: 3197-3201, 1998.
21. Murphy, L., and Watson, P. Steroid receptors in human breast tumorigenesis and breast cancer progression. Biomed. Pharmacother., 56: 65-77, 2002.
22. Jiang, S., and Jordan, V. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary cDNAs for estrogen receptor. J. Natl. Cancer Inst. (Bethesda), 84: 580-591, 1992.
23. Elston, C., and Ellis, I. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long term follow-up. Histopathology, 19: 403-410, 1991.
24. Page, D., Gray, R., Allred, D., Dressler, L., Hatfield, A., Martino, S., Robert, N., and Wood, W. Prediction of node-negative breast cancer outcome by histologic grading and S-phase analysis by flow cytometry. Am J. Clin. Oncol., 24: 10-18, 2001.
25. Parl, F., Schmidt, B., Dupont, W., and Wagner, R. Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis and histologic grading. Cancer (Phila.), 54: 2237-2242, 1984.
26. Martin, L., Farmer, I., Johnston, S., Ali, S., Marshall, C., and Dowsett, M. Enhanced ERalpha ERBB2 and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term oestrogen deprivation. J. Biol. Chem., 30458-30468, 2003.
27. Jeng, M., Yue, W., Eischeid, A., Wang, J., and Santen, R. Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breastcancer cells. Breast Cancer Res. Treat., 62: 167-175, 2000.
28. Oh, A., Lorant, L., Holloway, J., Miller, D., Kern, F., and El-Ashry, D. Hyperactivation of MAPK induces loss of ERα expression in breast cancer cells. Mol. Endocrinol., 15: 1344-1359, 2001.